Compare Equinix Inc (EQIX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Neurocrine Biosciences Inc — how do they compare? Equinix Inc trades at $1,011.13 (market cap $101.81B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Equinix Inc is far larger — about 7× Neurocrine Biosciences Inc's market cap, and Equinix Inc pays a 2% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EQIX | NBIX | |
|---|---|---|
Market Cap | $101.81B | $14.60B |
Volume | 442,874 | 1,075,694 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $185.50 |
52-Week Low | $726.09 | $123.10 |
Typical Hold Time | 110 Days | 23 Days |
Enterprise Value | $122.94B | $14.61B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,031.77, down 1.49% today, with strong analyst support (75% buy ratings) and a $1,250 consensus price target. The stock shows bullish technical signals with support at $1,025 and resistance at $1,042. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 and Q4 2025 missing. The company maintains robust revenue growth, expanding from $7.3B in 2022 to $9.2B in 2025, with net income margins improving to 14.64%. AI-driven data center demand is accelerating growth, with Equinix planning $5B-$7B annual investments.
Outlook remains positive due to strong AI infrastructure demand and interconnection growth, though elevated valuation ratios (P/E 66.39) and significant capital expenditures pose risks. Debt levels have risen, with debt-to-asset ratio increasing to 47.13% in 2025. The upcoming Q3 2026 earnings on October 28 will be critical for validating growth trajectory amid competitive pressures.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
